N/A N=7,052 Randomized Prevention

Blood Glucose Monitoring in Electronic Health Records

Diabetes Mellitus

Bottom Line

View on ClinicalTrials.gov: NCT03542487 ↗

Enrolled (actual)

7,052

Serious AEs

—

Results posted

Sep 2024

Primary outcome: Primary: Count of Participants Entering Flowsheet Data During Measurement Period, Extensive Margin — 4; 27; 44; 43 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Practice Orientation (Behavioral); Standard Reminder (Behavioral); Gift Card Reminder (Behavioral); Physician Reminders (Behavioral)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Inova Health Care Services
Primary completion: Oct 2018

Outcome Measures

Outcome	Result	p-value
PRIMARY Count of Participants Entering Flowsheet Data During Measurement Period, Extensive Margin	4; 15; 17; 20; 30	—
PRIMARY Participant A1c Test Results (as Percent A1c) at 26 Weeks	7.179; 7.327; 7.110; 7.227; 7.227	—
SECONDARY Count of Participants Entering Flowsheet Data During Measurement Period, Extensive Margin	4; 15; 17; 20; 30	—
SECONDARY Number of Days Participant Used Flowsheet, Intensive	0.011; 0.501; 0.350; 0.663; 0.691; 0.009	—
SECONDARY Count of Participants With an Open Physician Order for Electronic Glucose Flowsheet	5; 466; 589; 554; 573; 6	—
SECONDARY Number of Days Since Last HbA1c Test	196.369; 196.828; 205.607; 192.341; 210.748; 196.434	—
SECONDARY Participant A1c Test Results (as Percent A1c) at 14 Weeks	7.196; 7.276; 7.123; 7.183; 7.197	—
SECONDARY Count of Participants With Improvement of HbA1c Test Results	666; 155; 158; 160; 147; 961	—
SECONDARY Count of Participants With Percent A1c Below Benchmark of 7	1846; 388; 453; 442; 458; 1799	—
SECONDARY Total Secure Messages Sent by Participant	1.385; 1.407; 1.528; 1.434; 1.571; 1.128	—
SECONDARY Total Secure Messages Sent by Patient to Primary Care Provider	—	—
SECONDARY Total Secure Messages Sent by PCP to Patient	—	—
SECONDARY Total Number of Participant Phone Appointments	0.792; 0.827; 0.789; 0.849; 0.765; 1.442	—
SECONDARY Total Number of Participant In-person Appointments	1.275; 1.314; 1.251; 1.109; 1.191; 2.326	—
SECONDARY Count of Participants With Changes to Active Medication List	742; 135; 133; 141; 140; 1132	—
SECONDARY Prescription Orders	5.111; 5.912; 4.488; 4.733; 4.259; 9.296	—
SECONDARY Flowsheet Entry Values (Descriptive)	—	—

Summary

This multi-site randomized tral aims to test methods of increasing adoption and integration of blood glucose monitoring into electronic medical records, and to measure the impact of wide-scale adoption on health status of patients with diabetes. To investigate determinants of adoption, the research will combine and test doctor and patient focused approaches to encouraging patient use of blood glucose flow sheets through the online patient portal, MyChart. Adoption will be measured on both the extensive and intensive margin: the number of patients who enter data into the flowsheets at all during the study period, and the mean number of entries per patient during the study period. Conditional on statistically significant increases in adoption, the study will examine corresponding intent-to-treat effects on patient A1c, and consider other indicators of possible mechanisms through which A1c improves or does not improve.

Eligibility Criteria

Inclusion Criteria

Adult patients of Inova physicians at primary care sites other than Ashburn II Primary Care, Lake Ridge Primary Care and Springfield Primary Care
Current diabetes mellitus diagnosis
Active MyChart account at time of treatment administration

Exclusion Criteria

Patients who participating physicians identify as pregnant
Patients who participating physicians identify as having contraindications for tracking of blood glucose

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03542487). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.